scholarly article | Q13442814 |
P356 | DOI | 10.1007/S10549-011-1832-4 |
P698 | PubMed publication ID | 22037787 |
P50 | author | Laurence Vanlemmens | Q59690694 |
P2093 | author name string | Charles Fournier | |
Philippe Carpentier | |||
Philippe Vennin | |||
Jacques Bonneterre | |||
Véronique Servent | |||
Marie-Christine Baranzelli | |||
Hélène Kolesnikov-Gauthier | |||
P2860 | cites work | Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up | Q28306437 |
Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group | Q33837310 | ||
The role of chemotherapeutic drugs in the evaluation of breast tumour response to chemotherapy using serial FDG-PET | Q34048123 | ||
Prognostic significance of a complete pathological response after induction chemotherapy in operable breast cancer | Q36623843 | ||
Doxorubicin with cyclophosphamide followed by docetaxel every 21 days compared with doxorubicin and docetaxel every 14 days as preoperative treatment in operable breast cancer: the GEPARDUO study of the German Breast Group | Q40510447 | ||
Early (18)F-2-fluoro-2-deoxy-d-glucose positron emission tomography may identify a subset of patients with estrogen receptor-positive breast cancer who will not respond optimally to preoperative chemotherapy | Q43201544 | ||
Predictive value of [18F]FDG PET for pathological response of breast cancer to neo-adjuvant chemotherapy | Q45023411 | ||
18F-FDG PET/CT for early prediction of response to neoadjuvant chemotherapy in breast cancer. | Q46072247 | ||
The role of 18F-FDG PET/CT in evaluation of early response to neoadjuvant chemotherapy in patients with locally advanced breast cancer | Q46123246 | ||
Monitoring primary systemic therapy of large and locally advanced breast cancer by using sequential positron emission tomography imaging with [18F]fluorodeoxyglucose | Q46201991 | ||
Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27. | Q46765380 | ||
Monitoring primary breast cancer throughout chemotherapy using FDG-PET. | Q53525219 | ||
Monitoring of early response to neoadjuvant chemotherapy in stage II and III breast cancer by [18F]fluorodeoxyglucose positron emission tomography. | Q54671187 | ||
P433 | issue | 2 | |
P407 | language of work or name | English | Q1860 |
P921 | main subject | chemotherapy | Q974135 |
Fluorodeoxyglucose Positron Emission Tomography | Q130273243 | ||
P304 | page(s) | 517-525 | |
P577 | publication date | 2011-10-26 | |
P1433 | published in | Breast Cancer Research and Treatment | Q326085 |
P1476 | title | Predictive value of neoadjuvant chemotherapy failure in breast cancer using FDG-PET after the first course | |
P478 | volume | 131 |
Q36533964 | A Phase II Study of 3'-Deoxy-3'-18F-Fluorothymidine PET in the Assessment of Early Response of Breast Cancer to Neoadjuvant Chemotherapy: Results from ACRIN 6688 |
Q91744969 | A Qualitative Transcriptional Signature for Predicting Extreme Resistance of ER-Negative Breast Cancer to Paclitaxel, Doxorubicin, and Cyclophosphamide Neoadjuvant Chemotherapy |
Q38165388 | Clinical application of 18F-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography in breast cancer |
Q38090509 | Diagnostic and prognostic application of positron emission tomography in breast imaging: emerging uses and the role of PET in monitoring treatment response |
Q37254082 | Early assessment of breast cancer response to neoadjuvant chemotherapy by semi-quantitative analysis of high-temporal resolution DCE-MRI: preliminary results |
Q38422342 | Early prediction of response to neoadjuvant chemotherapy in breast cancer patients: comparison of single-voxel (1)H-magnetic resonance spectroscopy and (18)F-fluorodeoxyglucose positron emission tomography. |
Q39612494 | FDG-PET/CT and MRI for Evaluation of Pathologic Response to Neoadjuvant Chemotherapy in Patients With Breast Cancer: A Meta-Analysis of Diagnostic Accuracy Studies |
Q87621688 | Glycolytic activity with 18F-FDG PET/CT predicts final neoadjuvant chemotherapy response in breast cancer |
Q38059133 | Preoperative systemic therapy in locoregional management of early breast cancer: highlights from the Kyoto Breast Cancer Consensus Conference. |
Q28080621 | Role of positron emission tomography for the monitoring of response to therapy in breast cancer |
Q47822633 | Sequential (18)F-FDG PET/CT for early prediction of complete pathological response in breast and axilla during neoadjuvant chemotherapy. |
Q28077678 | The application of positron emission tomography (PET/CT) in diagnosis of breast cancer. Part II. Diagnosis after treatment initiation, future perspectives |
Q53063063 | The combination of FDG PET and dynamic contrast-enhanced MRI improves the prediction of disease-free survival in patients with advanced breast cancer after the first cycle of neoadjuvant chemotherapy. |
Q34569318 | The maximum standardized uptake value of 18 F-FDG PET scan to determine prognosis of hormone-receptor positive metastatic breast cancer |
Q53515259 | ⁹⁹mTc-3PRGD₂ SPECT to monitor early response to neoadjuvant chemotherapy in stage II and III breast cancer. |
Search more.